The TBC1D1 antibody is a crucial tool for studying the TBC1 domain family member 1 (TBC1D1) protein, a Rab GTPase-activating protein (RabGAP) involved in intracellular trafficking and metabolic regulation. TBC1D1 shares structural homology with the related protein AS160 (TBC1D4) and plays a role in insulin-stimulated glucose uptake by regulating GLUT4 translocation in skeletal muscle and adipose tissue. It acts as a molecular switch, integrating signals from AMP-activated protein kinase (AMPK) and Akt/PKB pathways to control energy homeostasis. Dysregulation of TBC1D1 has been linked to obesity, type 2 diabetes, and metabolic syndrome. Antibodies targeting TBC1D1 enable researchers to detect its expression, phosphorylation status (e.g., at Ser237 and Thr596), and interactions in techniques like Western blotting, immunohistochemistry, and immunoprecipitation. Species specificity (human, mouse, rat) and validation in knockout models are critical for reliable results. Studies using these antibodies have elucidated TBC1D1's role in exercise-induced glucose uptake, lipid metabolism, and crosstalk between insulin and leptin signaling. Its tissue-specific functions and post-translational modifications remain active research areas, highlighting the antibody's importance in dissecting metabolic disease mechanisms.